Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pawlak

Showing results (31-40 of 3,185) with videos related to

Pageof 319
Sort By:
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 22, 2007
Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Nephron. Clinical Practice|August 3, 2007
Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetesKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Thrombosis Research|July 29, 2014
oxLDL - the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patientsKrystyna Pawlak, Michal Mysliwiec, Dariusz Pawlak
Clinical Biochemistry|January 25, 2015
Endocan--the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular diseaseKrystyna Pawlak, Michal Mysliwiec, Dariusz Pawlak
Przeglad Lekarski|April 27, 2005
[Hypoxia involvement in erythropoiesis regulation--a new insight]Sebastian Pawlak, Dariusz Pawlak, Włodzimierz Buczko
Thrombosis Research|June 21, 2005
Oxidative stress effects fibrinolytic system in dialysis uraemic patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
American Journal of Nephrology|March 27, 2007
Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
American Journal of Nephrology|January 4, 2005
Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular diseaseKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Polskie Archiwum Medycyny Wewnetrznej|September 1, 2005
[Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure]Krystyna Pawlak, Dariusz Pawlak, Michał Myśliwiec
American Journal of Nephrology|November 23, 2006
Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Pageof 319

Showing results (31-40 of 3,185) with videos related to

Sort By:
Pageof 319
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 22, 2007
Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Nephron. Clinical Practice|August 3, 2007
Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetesKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Thrombosis Research|July 29, 2014
oxLDL - the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patientsKrystyna Pawlak, Michal Mysliwiec, Dariusz Pawlak
Clinical Biochemistry|January 25, 2015
Endocan--the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular diseaseKrystyna Pawlak, Michal Mysliwiec, Dariusz Pawlak
Przeglad Lekarski|April 27, 2005
[Hypoxia involvement in erythropoiesis regulation--a new insight]Sebastian Pawlak, Dariusz Pawlak, Włodzimierz Buczko
Thrombosis Research|June 21, 2005
Oxidative stress effects fibrinolytic system in dialysis uraemic patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
American Journal of Nephrology|March 27, 2007
Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
American Journal of Nephrology|January 4, 2005
Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular diseaseKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Polskie Archiwum Medycyny Wewnetrznej|September 1, 2005
[Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure]Krystyna Pawlak, Dariusz Pawlak, Michał Myśliwiec
American Journal of Nephrology|November 23, 2006
Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patientsKrystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
Pageof 319